333 terminated. 333 Phase 1, 106 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 333 | Terminated 333 |
| Phase 2 | 106 | Terminated 106 |
Follow Leukemia, Myeloid: new trials by email Literature Review of Leukemia, Myeloid trials Research Report on Leukemia, Myeloid
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Multiple CAR-T Cell Therapy Targeting AML CLL-1, CD33 and/or CD123-specific CAR gene-engineered T cells - Acute Myeloid Leukemia | Phase 1 / Phase 2 | Terminated | Shenzhen Geno-Immune Medical Institute | 10 | 2025-08-01 | 2026-11-02 |
| A Study to Evaluate S227928 as a Single Agent and in Combination With Venetoclax in Patients With R/R AML, MDS/AML, or CMML S227928, Venetoclax - Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)/AML | Phase 1 / Phase 2 | Terminated | Servier Bio-Innovation LLC | 13 | 2025-02-25 | 2026-03-30 |
| BSB-1001 in Patients Undergoing HLA-Matched Allogenic Hematopoietic Stem Cell Transplant for AML, ALL or MDS SOC + BSB-1001 Dose Escalation Cohort, SOC+BSB-1001 Expansion Dose - AML, Adult Recurrent, ALL, Recurrent, Adult | Phase 1 / Phase 2 | Terminated | BlueSphere Bio, Inc | 2 | 2025-02-04 | 2026-09-10 |
| Evaluate the Safety, Tolerability, Pharmacokinetic Profile, Efficacy of Bl-M11D1 BL-M11D1 - Relapsed/Refractory Acute Myeloid Leukemia | Phase 1 | Terminated | SystImmune Inc. | 52 | 2024-12-19 | 2026-09-24 |
| Venetoclax in Combination With Azacitidine (VEN/AZA) Followed by Donor Lymphocyte Infusion (DLI) for Patients With Very High-Risk Acute Myeloid Leukemia (AML) Undergoing Allogeneic Hematopoietic Cell Transplant (HCT) Venetoclax, Azacitidine, Donor Lymphocyte Infusion - Acute Myeloid Leukemia | Phase 1 | Terminated | Antonio M Jimenez Jimenez | 2 | 2024-12-04 | 2026-07-13 |
| Luveltamab Tazevibulin (STRO-002) in Infants and Children < 12 Years of Age With Relapsed/Refractory CBFA2T3::GLIS2 AML Luveltamab tazevibulin - Acute Myeloid Leukemia (AML) | Phase 1 / Phase 2 | Terminated | Sutro Biopharma, Inc. | 1 | 2024-12-04 | 2026-10-13 |
| Acute Myeloid Leukemia Treated With With NETrin Abs in Combination With [AZACITIDINE + VENETOCLAX] NP137, Azacitidine Injection, Venetoclax - Acute Myeloid Leukemia Refractory | Phase 1 / Phase 2 | Terminated | Centre Leon Berard | 1 | 2024-09-11 | 2025-02-20 |
| A Study to Investigate Natural Killer Cell Engager (SAR443579) With Different Agents in Participants With Hematological Malignancies SAR443579, venetoclax, azacitidine - Acute Myeloid Leukemia | Phase 1 / Phase 2 | Terminated | Sanofi | 7 | 2024-08-13 | 2026-10-19 |
| Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple Combination With Azacitidine and Venetoclax in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome BMS-986497, Azacitidine, Venetoclax - Acute Myeloid Leukemia, Myelodysplastic Syndrome | Phase 1 | Terminated | Bristol-Myers Squibb | 34 | 2024-05-29 | 2026-10-01 |
| CRISPR-Edited Allogeneic Anti-CLL-1 CAR-T Cell Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia CB-012 - Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory | Phase 1 | Terminated | Caribou Biosciences, Inc. | 12 | 2024-02-08 | 2025-06-11 |
| Donor-Derived Anti-CD33 CAR T Cell Therapy (VCAR33) in Patients With Relapsed or Refractory AML After Allogeneic Hematopoietic Cell Transplant VCAR33 - Leukemia, Myeloid, Acute | Phase 1 / Phase 2 | Terminated | Vor Biopharma | 38 | 2023-12-11 | 2025-07-29 |
| Tagraxofusp-erzs, an IL-3 Diphtheria Fusion Protein, in Combination With Gemtuzumab Ozogamicin in Patients With Relapsed/Refractory AML Dose Escalation -tagraxofusp-erzs, Dose Expansion at RP2D -tagraxofusp-erzs - Acute Myeloid Leukemia | Phase 1 | Terminated | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 7 | 2023-11-20 | 2026-06-25 |
| Eltanexor (KPT-8602) With Inqovi (Decitabine-Cedazuridine) in High-Risk Myelodysplastic Syndromes KPT-8602, Inqovi, Bone marrow aspirate - Myelodysplastic Syndromes | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 3 | 2023-11-14 | 2025-12-02 |
| Study to Evaluate Adverse Events and Movement of Intravenously (IV) Infused ABBV-787 in Adult Participants With Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) ABBV-787 - Acute Myeloid Leukemia | Phase 1 | Terminated | AbbVie | 36 | 2023-11-13 | 2025-03-06 |
| A Phase 1, Open-Label, Sequential Cross-over, Bioavailability/Bioequivalence Study to Compare the Pharmacokinetics of Oral Cladribine With the Reference Listed Drug, Intravenous Cladribine Cladribine - Leukemia, Myelodysplastic Syndromes | Phase 1 | Terminated | M.D. Anderson Cancer Center | 3 | 2023-10-09 | 2026-07-30 |
| Tomivosertib in Relapsed or Refractory Acute Myeloid Leukemia (AML) Biospecimen Collection, Tomivosertib - Acute Myeloid Leukemia | Phase 1 | Terminated | Northwestern University | 8 | 2023-09-29 | 2026-06-11 |
| Study of SGR-2921 in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome SGR-2921 - Acute Myeloid Leukemia, High-Risk and Very High-Risk Myelodysplastic Syndromes | Phase 1 | Terminated | Schrödinger, Inc. | 66 | 2023-09-27 | 2025-09-22 |
| Study of Elenestinib (BLU-263) in Advanced Systemic Mastocytosis (AdvSM) and and Other KIT Altered Hematologic Malignancies BLU-263, Azacitidine - Advanced Systemic Mastocytosis | Phase 1 | Terminated | Blueprint Medicines Corporation | 9 | 2023-09-25 | 2025-04-10 |
| A Study of GDX012 in Adults With Relapsed or Refractory Acute Myeloid Leukemia GDX012, Chemotherapy Agents - Leukemia | Phase 1 / Phase 2 | Terminated | Takeda | 16 | 2023-07-11 | 2026-09-25 |
| A Study to Investigate Use of Off-the-shelf Natural Killer (NK) Cells (SAR445419) in Relapsed/Refractory Acute Myeloid Leukemia SAR445419, fludarabine, cytarabine - Acute Myeloid Leukaemia | Phase 1 | Terminated | Sanofi | 7 | 2023-06-16 | 2026-06-05 |
Showing 20 of 333. Sign in to see all of them.
Leukemia, Myeloid, Acute (289) · Myelodysplastic Syndromes (99) · Leukemia (73) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (64) · Recurrence (45) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (42) · Leukemia, Myelomonocytic, Chronic (32) · Leukemia, Lymphocytic, Chronic, B-Cell (30) · Multiple Myeloma (30) · Lymphoma, Non-Hodgkin (28) · Blast Crisis (25) · Congenital Abnormalities (25) · Neoplasms (19) · Hematologic Neoplasms (18) · Lymphoma, Large B-Cell, Diffuse (18)
Hemic and Lymphatic Diseases (333) · Neoplasms by Histologic Type (331) · Hematologic Diseases (330) · Neoplasms (314) · Leukemia (260) · Bone Marrow Diseases (158) · Pathologic Processes (143) · Pathological Conditions, Signs and Symptoms (143) · Disease Attributes (139) · Chronic Disease (104) · Immune System Diseases (97) · Immunoproliferative Disorders (95) · Lymphoproliferative Disorders (93) · Lymphatic Diseases (91)
Azacitidine (46) · Cytarabine (45) · venetoclax (38) · fludarabine (26) · Cyclophosphamide (25) · fludarabine phosphate (16) · Decitabine (13) · Mitoxantrone (10) · Busulfan (9) · Dasatinib (9) · Etoposide (9) · Daunorubicin (8) · Filgrastim (7) · Gemtuzumab (7) · Clofarabine (6)
M.D. Anderson Cancer Center (32) · National Cancer Institute (NCI) (14) · AbbVie (7) · Novartis Pharmaceuticals (7) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (7) · Amgen (6) · Celgene (6) · Fred Hutchinson Cancer Center (6) · Masonic Cancer Center, University of Minnesota (6) · Merck Sharp & Dohme LLC (6) · Washington University School of Medicine (6) · AstraZeneca (4) · Incyte Corporation (4) · Northwestern University (4) · University of Pennsylvania (4)
United States (278) · France (36) · Spain (36) · Canada (29) · Germany (25) · Italy (23) · Australia (20) · United Kingdom (16) · Netherlands (14) · Belgium (12) · China (11) · Japan (11) · South Korea (10) · Israel (7) · Poland (5)
Roger Strair, MD, PhD (3) · Aude Chapuis (2) · Courtney DiNardo, MD (2) · Ehab Atallah, MD (2) · Farhad Ravandi-Kashani (2) · Farhad Ravandi-Kashani, MD (2)
PMID 33197925, PMID 17151364, PMID 19010875, PMID 19029442, PMID 19139736, PMID 19503090, PMID 20460644, PMID 20563869, PMID 21145590, PMID 21494838, PMID 22080968, PMID 22987312, PMID 23092873, PMID 23256542, PMID 23393050, PMID 23400739, PMID 24200998, PMID 24355079, PMID 25441108, PMID 27544076, PMID 28161120, PMID 28280089, PMID 29042364, PMID 29142066, PMID 29296751, PMID 29339097, PMID 30361262, PMID 30559424, PMID 31235963, PMID 31527168, PMID 32462078, PMID 32476546, PMID 32521310, PMID 33194741, PMID 33208914, PMID 33554732, PMID 33787078, PMID 34245496, PMID 34247273, PMID 34253595, PMID 34797911, PMID 35046058, PMID 35063965, PMID 35180323, PMID 35829925, PMID 36007102, PMID 36063832, PMID 36226495, PMID 36658425, PMID 36841672
2018 (9), 2017 (6), 2023 (6), 2019 (4), 2014 (3), P01CA018029 (3), P30CA006973 (3), P30CA015704 (3), P30CA016672 (3), P30CA072720 (3), 2015 (2), 2016 (2), N01CM62203 (2), P30CA060553 (2), P30CA124435 (2)